- Investing Ideas
- /
- Chinese Pharmaceuticals & Biotech Undervalued based on future growth
Chinese Pharmaceuticals & Biotech Undervalued based on future growth
Results
3
0 new
Companies which can be considered undervalued when accounting for expected future growth (PEG under 0.8)
3 companies
Nanjing King-Friend Biochemical PharmaceuticalLtd
Market Cap: CN¥14.6b
Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd.
603707
CN¥9.03
7D
-2.0%
1Y
-26.3%
Pacific Shuanglin Bio-pharmacy
Market Cap: CN¥13.0b
Engages in research, development, production, and sales of blood products in China and internationally.
000403
CN¥13.69
7D
-3.2%
1Y
-17.9%
KPC PharmaceuticalsInc
Market Cap: CN¥9.5b
A pharmaceutical company, engages in the research and development, production, marketing, and commercial wholesale of botanical drugs and natural drugs in the People’s Republic of China and internationally.
600422
CN¥12.56
7D
-0.8%
1Y
-19.6%